NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
AI Model Predicts Growth Spurts from Pediatric Neck X-rays for Orthodontics
Korean researchers developed an AI system (ARNet-v2) that predicts children's growth spurts from neck X-rays to enhance orthodontic treatment planning.
•EurekAlert
Dana-Farber Showcases AI and Clinical Trial Advances at ESMO 2025
Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
•EurekAlert
Einstein College Awarded $18M NIH Grant to Develop AI Tools for Mental Health Crisis Prediction
Albert Einstein College of Medicine received an $18 million NIH grant to create AI-based tools for predicting mental health crises using cognitive monitoring.